KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 78 filers reported holding KINNATE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $524 | -28.0% | 374,291 | +55.7% | 0.04% | -38.4% |
| Q2 2023 | $728 | +213.8% | 240,343 | +547.4% | 0.07% | +217.4% |
| Q1 2023 | $232 | -45.8% | 37,123 | -47.1% | 0.02% | -56.6% |
| Q4 2022 | $428 | -100.0% | 70,174 | -4.2% | 0.05% | -54.3% |
| Q3 2022 | $876,000 | +23.2% | 73,277 | +30.0% | 0.12% | +8.4% |
| Q2 2022 | $711,000 | +33.9% | 56,379 | +19.5% | 0.11% | +50.7% |
| Q1 2022 | $531,000 | – | 47,175 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |